The correct answer is B, "Review microbiology laboratory reports for enteric organisms in the past week," as this is the first action the infection preventionist (IP) should perform following the alert of a sewer main break and potential contamination of the city water supply. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, a rapid assessment of existing data is a critical initial step in investigating a potential waterborne outbreak. Reviewing microbiology laboratory reports for enteric organisms (e.g., Escherichia coli, Salmonella, or Shigella) helps the IP identify any recent spikes in infections that could indicate water supply contamination, providing an evidence-based starting point for the investigation (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.2 - Analyze surveillance data). This step leverages available hospital data to assess the scope andurgency of the situation before initiating broader actions.
Option A (notify the Emergency and Admissions departments to report diarrhea cases to infection control) is an important subsequent step to enhance surveillance, but it relies on proactive reporting and does not provide immediate evidence of an ongoing issue. Option C (contact the Employee Health department and ask for collaboration in case-finding) is valuable for involving additional resources, but it should follow the initial data review to prioritize case-finding efforts based on identified trends. Option D (review the emergency preparedness plan with engineering for sources of potable water) is a critical preparedness action, but it is more relevant once contamination is confirmed or as a preventive measure, not as the first step in assessing the current situation.
The focus on reviewing laboratory reports aligns with CBIC's emphasis on using surveillance data to guide infection prevention responses, enabling the IP to quickly determine if the sewer main break has already impacted patient health and to escalate actions accordingly (CBIC Practice Analysis, 2022, Domain II:
Surveillance and Epidemiologic Investigation, Competency 2.1 - Conduct surveillance for healthcare- associated infections and epidemiologically significant organisms). This approach is consistent with CDC guidelines for responding to waterborne outbreak alerts (CDC Environmental Public Health Guidelines, 2020).
References: CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competencies 2.1 - Conduct surveillance for healthcare-associated infections and epidemiologically significant organisms, 2.2 - Analyze surveillance data. CDC Environmental Public Health Guidelines, 2020.

The correct answer is C, "Mucormycosis," as it is the infectious disease associated with environmental fungi.
According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, mucormycosis is caused by fungi belonging to the order Mucorales, which are commonly found in the environment, including soil, decaying organic matter, and contaminated water. These fungi can become opportunistic pathogens, particularly in immunocompromised individuals, leading to severe infections such as rhinocerebral, pulmonary, or cutaneous mucormycosis (CBIC Practice Analysis, 2022, Domain I:
Identification of Infectious Disease Processes, Competency 1.1 - Identify infectious disease processes).
Environmental exposure, such as inhalation of fungal spores or contact with contaminated materials, is a primary mode of transmission, making it directly linked to environmental fungi.
Option A (Listeriosis) is caused by the bacterium Listeria monocytogenes, typically associated with contaminated food products (e.g., unpasteurized dairy or deli meats) rather than environmental fungi. Option B (Hantavirus) is a viral infection transmitted through contact with rodent excreta, not fungi, and is linked to environmental reservoirs like rodent-infested areas. Option D (Campylobacter) is a bacterial infection caused by Campylobacter species, often associated with undercooked poultry or contaminated water, and is not related to fungi.
The association of mucormycosis with environmental fungi underscores the importance of infection prevention strategies, such as controlling environmental contamination and protecting vulnerable patients, which aligns with CBIC's focus on identifying and mitigating risks from infectious agents in healthcare settings (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.2 - Implement measures to prevent transmission of infectious agents). This knowledge is critical for infection preventionists to guide environmental cleaning and patient care protocols.
References: CBIC Practice Analysis, 2022, Domain I: Identification of Infectious Disease Processes, Competency 1.1 - Identify infectious disease processes; Domain III: Infection Prevention and Control, Competency 3.2 - Implement measures to prevent transmission of infectious agents.

The correct answer is D, "A device used one time on a patient during a procedure and then discarded," as this accurately describes a single-use medical device. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, a single-use device (SUD), also known as a disposable device, is labeled by the manufacturer for one-time use on a patient and is intended to be discarded afterward to prevent cross-contamination and ensure patient safety. This definition is consistent with regulations from the Food and Drug Administration (FDA), which designate SUDs as devices that should not be reprocessed or reused due to risks of infection, material degradation, or failure to restore sterility (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). Examples include certain syringes, catheters, and gloves, which are designed for single use to eliminate the risk of healthcare-associated infections (HAIs).
Option A (a device which can be used on a single patient) is too vague and could apply to both single-use and reusable devices, as reusable devices are also often used on a single patient per procedure before reprocessing.
Option B (a device that is sterilized and can be used again on the same patient) describes a reusable device, not a single-use device, as sterilization and reuse are not permitted for SUDs. Option C (a device used on a patient and reprocessed prior to being used again) refers to a reusable device that undergoes reprocessing (e.
g., sterilization), which is explicitly prohibited for SUDs under manufacturer and regulatory guidelines.
The focus on discarding after one use aligns with CBIC's emphasis on preventing infection through adherence to device labeling and safe reprocessing practices, ensuring that healthcare facilities avoid the risks associated with improper reuse of SUDs (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.5 - Evaluate the environment for infection risks). This practice is critical to maintaining a sterile and safe healthcare environment.
References: CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competencies 3.3 - Ensure safe reprocessing of medical equipment, 3.5 - Evaluate the environment for infection risks. FDA Guidance on Reprocessing of Single-Use Devices, 2016.

The correct answer is B, "Fishbone diagram," as this is the most appropriate quality tool for the team to use when determining what has contributed to the recent increase in catheter-associated urinary tract infections (CAUTIs). According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, the fishbone diagram, also known as an Ishikawa or cause-and-effect diagram, is a structured tool used to identify and categorize potential causes of a problem. In this case, the team needs to explore the root causes of the CAUTI increase, which could include factors such as improper catheter insertion techniques, inadequate maintenance, staff training gaps, or environmental issues (CBIC Practice Analysis, 2022, Domain II:
Surveillance and Epidemiologic Investigation, Competency 2.2 - Analyze surveillance data). The fishbone diagram organizes these causes into categories (e.g., people, process, equipment, environment), facilitating a comprehensive analysis and guiding further investigation or intervention.
Option A (gap analysis) is useful for comparing current performance against a desired standard or benchmark, but it is more suited for identifying deficiencies in existing processes rather than uncovering the specific causes of a recent increase. Option C (plan, do, study, act [PDSA]) is a cyclical quality improvement methodology for testing and implementing changes, which would be relevant after identifying causes and designing interventions, not as the initial tool for root cause analysis. Option D (failure mode and effect analysis [FMEA]) is a proactive risk assessment tool used to predict and mitigate potential failures in a process before they occur, making it less applicable to analyzing an existing increase in CAUTIs.
The use of a fishbone diagram aligns with CBIC's emphasis on using data-driven tools to investigate and address healthcare-associated infections (HAIs) like CAUTIs, supporting the team's goal of pinpointing contributory factors (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.3 - Identify risk factors for healthcare-associated infections). This tool's visual and collaborative nature also fosters team engagement, which is essential for effective problem-solving in infection prevention.
References: CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competencies 2.2 - Analyze surveillance data, 2.3 - Identify risk factors for healthcare-associated infections.

The correct answer is D, "Manufacturer representatives," as they are responsible for providing information regarding clinical trials when evaluating environmental cleaning and disinfectant products as part of the product evaluation committee. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, manufacturers are the primary source of data on the efficacy, safety, and performance of their products, including clinical trial results that demonstrate the disinfectant's ability to reduce microbial load or prevent healthcare-associated infections (HAIs) (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.4 - Implement environmental cleaning and disinfection protocols).
This information is critical for the committee to assess whether the product meets regulatory standards (e.g., EPA registration) and aligns with infection prevention goals, and it is typically supported by documentation such as peer-reviewed studies or trial data provided by the manufacturer.
Option A (Infection Preventionist) plays a key role in evaluating the product's fit within infection control practices and may contribute expertise or conduct internal assessments, but they are not responsible for providing clinical trial data, which originates from the manufacturer. Option B (Clinical representatives) can offer insights into clinical usage and outcomes but rely on manufacturer data for trial evidence rather than generating it. Option C (Environmental Services) focuses on the practical application and cleaning processes but lacks the authority or resources to conduct or provide clinical trial information.
The reliance on manufacturer representatives aligns with CBIC's emphasis on evidence-based decision- making in product selection, ensuring that the product evaluation committee bases its choices on robust, manufacturer-supplied clinical data (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 - Use data to guide infection prevention and control strategies).
This approach supports the safe and effective implementation of environmental cleaning products in healthcare settings.
References: CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 - Use data to guide infection prevention and control strategies; Domain III: Infection Prevention and Control, Competency 3.4 - Implement environmental cleaning and disinfection protocols.